Induction of senescence permanently restricts cellular proliferation after oncogenic stimulation thereby acting as a potent barrier to tumor development. The relevant effector proteins may therefore be fundamental to cancer development. A recent study identified IGFBP7 as a secreted factor mediating melanocyte senescence induced by oncogenic B-RAF, which is found commonly in cutaneous nevi. In contrast to the previous report, we demonstrate that B-RAF signaling does not induce IGFBP7 expression, nor the expression of the IGFBP7 targets, BNIP3L, SMARCB1, or PEA15, in human melanocytes or fibroblasts. We also found no correlation between B-RAF mutational status and IGFBP7 protein expression levels in 22 melanoma cell lines, 90 melanomas, and 46 benign nevi. Furthermore, using a lentiviral silencing strategy we show that B-RAF induces senescence in melanocytes and fibroblasts, irrespective of the presence of IGFBP7. Therefore, we conclude that the secreted protein IGFBP7 is dispensable for B-RAF V600E -induced senescence in human melanocytes.
INTRODUCTION
Cutaneous melanoma is an aggressive form of cancer that is highly resistant to conventional therapies with fewer than 10% of patients with visceral metastases surviving 2 years (reviewed in Thompson et al., 2005; Herlyn, 2007) . It may arise de novo from melanocytes or their precursors in the skin (Kelly et al., 1997) or from common benign clonal expansions of cutaneous melanocytes, known as nevi (Chin et al., 2006; reviewed in Bennett, 2008) . Although the presence of high numbers of nevi is strongly associated with melanoma risk, the majority of benign nevi lack proliferative activity and never progress into malignancy despite harboring oncogenic alterations. Indeed, constitutively activating mutations affecting the N-RAS or B-RAF kinase components of the mitogen-activated protein kinase (MAPK) pathway are found in over 80% of benign nevi (Bauer et al., 2007; Papp et al., 1999; Pollock et al., 2003) . The prevailing view is that nevi have initiated a permanent form of proliferative arrest known as oncogene-induced senescence (reviewed in Prieur and Peeper, 2008) . Certainly, benign nevi display several markers of senescence growth arrest, including increased senescence-associated b-galactosidase (SA-b-Gal) activity and p16
INK4a expression (Gray-Schopfer et al., 2006; Michaloglou et al., 2005) . Although the presence of senescent cells in human melanocytic nevi remains controversial (Cotter et al., 2007) , accumulating evidence suggests that senescence occurs in vivo and acts as an effective barrier to tumor formation (reviewed in Prieur and Peeper, 2008) . In this regard, identification of the molecules that enforce oncogene-induced arrest in human melanocytes is of prime importance as their loss may be a critical step in the escape of malignant clones and the consequent development of melanoma. These molecules are also potential therapeutic targets, as reinstating their functions may stimulate entry into senescence.
In an attempt to identify these molecules, a genome-wide loss-of-function screen was used to define essential regulators of B-RAF V600E -induced senescence (Wajapeyee et al., 2008) . Notably, this oncogenic form of B-RAF occurs in 40%-50% of melanomas (reviewed in Platz et al., 2008) and its expression is sufficient to induce senescence and apoptosis in human diploid fibroblasts and melanocytes (Gray-Schopfer et al., 2006; Michaloglou et al., 2005; Wajapeyee et al., 2008) . Seventeen genes were identified and the suppression of each permitted diploid human fibroblasts to proliferate and survive in the presence of oncogenic B-RAF V600E . Among these were p53 and the insulin-like growth factor (IGF) binding protein 7 (IGFBP7). IGFBP7 is a secreted protein that reduces the bioavailability of insulin/IGF in peripheral blood and has been implicated in tumor suppression of breast, colon, lung, and pancreatic cancers (Burger et al., 1998; Chen et al., 2007; Landberg et al., 2001; Ruan et al., 2007; Swisshelm et al., 1995; Ye et al., 2007) .
B-RAF V600E was also shown to upregulate IGFBP7 expression via the B-RAF-MEK-ERK signaling cascade. IGFBP7 inhibited , or copGFP. The efficiency of transduction was controlled with the coexpression of copGFP and was consistently above 90%. Cell proliferation (Ki67), chromatin condensation (DAPI), and the appearance of increased SA-b-Gal activity were analyzed and quantitated 5 and 10 days after infection of melanocytes and fibroblasts, respectively. Cells enlarged to show DAPI-stained chromatin foci are indicated with arrows. Percentage of cells positive for the indicated marker is shown in histograms, which correspond to the mean ± standard deviation (SD) of at least two independent transduction experiments from a total of at least 300 cells. phosphorylation of MEK by B-RAF, initiating a negative-feedback loop. Consistent with the hypothesis that IGFBP7 suppresses early B-RAF-driven tumor formations in vivo, expression of IGFBP7 was highly expressed in B-RAF V600E -positive nevi and in primary melanomas and melanoma cell lines lacking activated B-RAF but was lost in B-RAF V600E -positive melanomas and melanoma cell lines. Furthermore, purified recombinant IGFBP7 potently suppressed the growth of B-RAF
V600E
-positive human melanomas but had no effect on tumors with wild-type B-RAF (Wajapeyee et al., 2008) . Taken together these observations suggest that IGFBP7 is essential in constraining B-RAF V600E -stimulated cell proliferation. In this work we readdressed the role of IGFBP7 in B-RAF V600E -induced senescence in diploid human melanocytes. This was particularly important as two recent reports did not detect a correlation between B-RAF mutation status and IGFBP7 expression in a panel of primary melanomas and metastases (Schrama et al., 2009; Wajapeyee et al., 2009 ). We also found no correlation between B-RAF mutational status and IGFBP7 expression levels in a series of melanoma cell lines, melanomas, and benign nevi. Furthermore, in contrast to the previous report (Wajapeyee et al., 2008) , we demonstrate that B-RAF signaling does not induce IGFBP7 expression in either human melanocytes or fibroblasts, and using a lentiviral silencing strategy we show that B-RAF potently induces senescence in the presence and absence of IGFBP7. Therefore, we conclude that the secreted protein IGFBP7 is dispensable for B-RAF V600E -induced senescence in human melanocytes.
RESULTS

Expression of Oncogenic B-RAF Induces Cellular
Senescence that Is Associated with IGFBP7 Repression To evaluate the response of human cells to oncogenic B-RAF, the melanoma-associated B-RAF V600E mutant was stably transduced into primary diploid HEM1455 melanocytes and HDF1314 epidermal fibroblasts using lentiviral vectors coexpressing Copepod GFP (copGFP). Viral titers were selected to provide an efficiency of infection above 90% and activation of the ERK pathway that was comparable to human melanoma cells expressing endogenous B-RAF V600E ( Figure 1A ). As expected from previous studies, expression of oncogenic B-RAF efficiently blocked cellular proliferation and induced SAb-Gal activity as early as 5 days after infection ( Figure 1B ). The majority of B-RAF V600E -transduced melanocytes and fibroblasts displayed several markers of oncogene-driven senescence, increased SA-b-Gal expression, senescence-associated heterochromatin foci (SAHF), and significantly decreased Ki67 expression ( Figure 1B) . Each focus in a senescent cell results from condensation of an individual chromosome and is enriched for common markers of heterochromatin, including histone H3 methylated at lysine 9 (H3K9Me) and the nonhistone chromatin protein HMGA2 ( Figure 1C ) (reviewed in Adams, 2007) . The accumulation of oncogenic B-RAF V600E in both melanocytes and fibroblasts was associated with increased levels of phosphorylated ERK and induction of the CDK inhibitor p16 INK4a . In addition, the levels of p53 were significantly repressed and expression of the p53-transcription target p21
Waf1 remained low or was reduced by the accumulation of B-RAF V600E ( Figure 1D ). It has been suggested that senescence triggered by oncogenic B-RAF is associated with the transcriptional upregulation of IGFBP7 (Wajapeyee et al., 2008) . We therefore reanalyzed the expression of IGFBP7 and conclusively show that oncogenic B-RAF represses, rather than induces, IGFBP7 expression in both human melanocytes and fibroblasts ( Figure 2A and Figure S1 available online). Indeed, B-RAF V600E -transduced melanocytes and fibroblasts displayed diminished levels of cellular and secreted IGFBP7 compared to the control copGFP-transduced cells ( Figure 2A and Figure S1 ). The depletion of IGFBP7 was routinely observed as early as 2 days post-B-RAF V600E transduction and was maintained for the duration of the transduction experiments (5 days and 15 days post-transduction of melanocytes and fibroblasts, respectively). The slight increase in secreted IGFBP7 in melanocytes, 2 days post-transduction with oncogenic B-RAF V600E , was not consistent over replicate experiments and did not correspond with an increase in cellular IGFBP7 at this time point (Figure 2A ). The depletion of IGFBP7 occurred earlier than the onset of BRAF V600E -induced senescence (see Figure 1B) . Furthermore, the specific silencing of oncogenic B-RAF or the addition of a MEK inhibitor led to the accumulation of IGFBP7 in melanoma cell lines expressing the B-RAF V600E variant ( Figure 2B ).
B-RAF Mutation Status Does Not Correlate with IGFBP7 Expression
To further scrutinize the correlation of IGFBP7 expression with B-RAF mutation status, we analyzed a series of 22 melanoma cell lines for IGFBP7 expression. In this series, we did not find a correlation between IGFBP7 expression and B-RAF mutation status, as IGFBP7 was detected in 10/14 B-RAF mutant and 3/8 B-RAF wild-type tumor lines ( Figure 2C ). Further, we found no correlation between B-RAF mutation status and IGFBP7 transcript levels in gene expression microarray analyses of 99 metastatic melanoma tumors ( Figure 3A , Table 1 ). This was confirmed at the protein level by tissue microarray analyses of 90 of these tumors ( Figure 3B , Table 2 ). Consistent with these data, we did not observe increased expression of several IGFBP7-regulated gene products, including SMARCB1, BNIP3L, and PEA15 (Wajapeyee et al., 2008) , in B-RAF
V600E
-transduced fibroblasts or melanocytes ( Figure 3C ), nor did the expression of these IGFBP7-regulated transcripts correlate with B-RAF mutation status in our microarray analyses of 99 metastatic melanomas ( Figure 3C , Table 1 ). Finally, IGFBP7 protein expression did not correlate with B-RAF mutation status in a series of human benign nevi ( Figure 3D , Table 2 ). Collectively these data indicate that B-RAF V600E does not upregulate IGFBP7 expression in fibroblasts or melanocytes nor is the loss of IGFBP7 required for the development of B-RAF V600E -positive melanomas.
IGFBP7 Is Not Required for B-RAF V600E -Induced Senescence
To specifically examine the contribution of IGFBP7 to B-RAFmediated senescence, we applied lentiviral shRNA vectors that specifically suppress the expression of IGFBP7. To minimize confounding effects of shRNA off-target silencing two independent silencing molecules targeting IGFBP7 were generated (Wajapeyee et al., 2008) . These silencing constructs were highly effective in silencing the expression of IGFBP7. The role of IGFBP7 in oncogene-induced senescence was evaluated in human melanocytes (HEM1455, nHEM) and fibroblasts (HDF1314, WS1, and BJ), and the results for HDF1314 and HEM1455 are depicted in detail. Cells were transduced with an IGFBP7 shRNA molecule coexpressing copGFP and 3 days post-infection were retransduced with lentiviral vectors expressing B-RAF V600E with copGFP or copGFP alone. All experiments included a negative control shRNA molecule without homology to any human gene. Just as in our previous single transduction experiments, transduction efficiencies reached at least 90% in all cells ( Figure S2A ) and there was no need for antibiotic selection. This strategy proved effective as the depletion of pRb along with p53 using highly effective short-hairpin RNAs (Haferkamp et al., 2009a) overcame B-RAF V600E -induced melanocyte cell-cycle arrest ( Figure S2B ). As expected, all melanocytes and fibroblasts transduced with the combination of control shRNA and B-RAF V600E expressed markers associated with the onset of senescence. These included significantly reduced levels of the proliferation marker Ki67, accumulation of SAHF, and increased SA-b-Gal activity ( Figures 4A and 4B) . Importantly, inhibition of IGFBP7 expression did not alter the growth arrest induced by oncogenic B-RAF
V600E
, and cells were arrested after infection, stained positive for SA-b-Gal, and accumulated DAPI-stained foci regardless of the expression level of IGFBP7 ( Figures 4A and 4B) . In addition, the induction of p16
INK4a associated with oncogenic B-RAF expression was also maintained in melanocytes and fibroblasts regardless of IGFBP7 expression ( Figure 5 ). Similar results were obtained when IGFBP7-silenced fibroblasts (data not shown) and melanocytes were selected using puromycin prior to reinfection with oncogenic B-RAF V600E ( Figure S2C ). This antibiotic selection strategy resembled the experimental design employed by Wajapeyee et al. (2008) and confirmed that IGFBP7 was not essential for B-RAF V600E -induced senescence as its depletion did not prevent cell-cycle arrest, formation of DAPI-stained foci, or the induction of SA-b-Gal activity ( Figure S2C ).
DISCUSSION
The detection of senescent cells in vivo suggests that senescence is a genuine, physiological tumor suppressor mechanism, and this notion has intensified the search for the molecules that initiate and maintain this proliferative arrest. In a landmark study, a genome-wide shRNA screen identified 17 genes that were essential for B-RAF V600E -induced senescence in human fibroblasts and melanocytes. Two of these essential candidates were p53 and the secreted protein IGFBP7 (Wajapeyee et al., 2008) . We and others have shown that p53 levels are not induced by oncogenic B-RAF in human melanocytes (Gray-Schopfer et al., 2006; Zhuang et al., 2008) or in senescent normal melanocytes (Sviderskaya et al., 2003) . Furthermore, several reports have confirmed that inactivation of p53 alone does not prevent B-RAF-induced senescence in melanocytes (Denoyelle et al., 2006; Zhuang et al., 2008) . In keeping with these findings, immortal melanocytes accumulating oncogenic B-RAF and silenced for p53 expression did arise in one investigation. However, these immortal cells had acquired a substantial deletion in chromosome 13, which encodes the pRb1 tumor suppressor gene (Yu et al., 2009 ). Indeed, loss of both pRb and p53 is sufficient to overcome both N-RAS Q61K - (Haferkamp et al., 2009a) and B-RAF V600E -induced ( Figure S2B ) senescence in melanocytes. Collectively these data strongly indicate that p53 is not required for B-RAF-induced senescence in melanocytes in vitro and in vivo.
Because IGFBP7 might also have clinical potential, we used four independent experimental strategies to reanalyze the reported contribution of IGFBP7 to B-RAF-induced senescence. First, we examined the regulation of IGFBP7 by oncogenic B-RAF in several melanocyte and fibroblast cells. We did not detect any significant upregulation of IGFBP7 in response to oncogenic B-RAF. In fact we saw significant reduction in IGFBP7 in all primary cells tested, and a slight IGFBP7 upregulation was only seen in response to silencing of B-RAF V600E or inhibiting the MAPK pathway using a MEK inhibitor in melanoma cell lines harboring oncogenic B-RAF V600E . IGFBP7 is transcriptionally regulated by p53 (Suzuki et al., 2009) , and the depletion of IGFBP7 in response to oncogenic B-RAF may be due to the transcriptional repression of p53. Second, two independent and highly effective IGFBP7 shRNA molecules were employed to examine the role of IGFBP7 in B-RAF-induced senescence. We found that B-RAF effectively induced senescence regardless of IGFBP7 expression in the two melanocyte and three fibroblast strains tested. Third, there was no correlation between IGFBP7 expression and B-RAF mutation status in a panel of 22 melanoma cell lines. Fourth, immunohistochemical analysis of human nevi and melanoma samples with known B-RAF mutation status confirmed that IGFBP7 expression was not related to B-RAF activation in vivo. The interpretation of the melanoma tumor data is not straightforward, however, as it is not possible to rule out the influence of environmental and genetic risk factors present in the Australian melanoma patients. The Australian population is generally exposed to high levels of ultraviolet radiation and develops melanocytic nevi early in life and in large numbers (Harrison et al., 2008) . There is evidence that interactions among phenotypic, genetic, and environmental risk factors may influence the mechanisms of melanoma development (Curtin et al., 2006; Falchi et al., 2009) . Thus, the lack of correlation between IGFBP7 expression and B-RAF mutation status in this cohort may reflect differences in genetic characteristics and environmental risk factors. Never- Figure S2A ). Three days post-infection the cells were reinfected with lentiviruses encoding B-RAF V600E or copGFP, as shown. Cell proliferation (Ki67), chromatin condensation (DAPI), and SA-b-Gal activity were analyzed. Representative examples at 5 days after B-RAF infection are shown. Cell counts for each of these markers are shown as histograms, which correspond to the mean ± SD of at least two independent transduction experiments from a total of at least 300 cells (see also Figures S2B and S2C ).
(B) Fibroblasts were transduced with lentiviruses containing the indicated shRNA constructs (see Figure S2A ). Three days post-infection the cells were retransduced with copGFP control lentivirus (À) or lentiviruses expressing B-RAF V600E or copGFP, as shown. Cell proliferation (Ki67), chromatin condensation (DAPI), and the appearance of SA-b-Gal activity were analyzed as detailed above on days 5, 10, and 15 post-second transduction. Representative examples at 10 days after B-RAF infection are shown. Cell counts for each of the markers are shown as histograms, which correspond to the mean ± SD of at least two independent transduction experiments from a total of at least 300 cells.
theless, two recent reports also failed to detect a correlation between IGFBP7 expression and B-RAF status in melanoma metastases (Schrama et al., 2009; Wajapeyee et al., 2009) . From all observations, we conclude that IGFBP7 expression is not induced by oncogenic B-RAF. Moreover, IGFBP7 expression seems dispensable for B-RAF-induced senescence in human melanocytes, fibroblasts, and nevi. It is also notable that although IGFBP7 is thought to act as a tumor suppressor in some cancers (Burger et al., 1998; Chen et al., 2007; Landberg et al., 2001; Ruan et al., 2007; Swisshelm et al., 1995; Ye et al., 2007) , it is overexpressed in glioblastomas and gastric, prostate, and colorectal cancers (Akaogi et al., 1996; Degeorges et al., 1999; Jiang et al., 2008; Pen et al., 2007 Pen et al., , 2008 Shao et al., 2004; Takeno et al., 2008) , which argues against it having a purely tumor suppressive role. Because the primary goal of this study was to analyze the contribution of IGFBP7 in B-RAF-mediated senescence, we did not analyze the effect of recombinant IGFBP7 on primary melanocytes, especially given that we could not confirm any correlation between IGFBP7 expression and B-RAF mutation status.
However, although recombinant IGFBP7 induced apoptosis in BRAF mutation-positive cancer cell lines (Wajapeyee et al., 2008) , it also promoted cell death in a subset of human cancer cells with wild-type B-RAF that did not respond to the MEK inhibitor U0126 (Wajapeyee et al., 2009 ). These findings suggest that the impact of recombinant IGFBP7 may be independent of the MAPK pathway.
The most likely explanation for the disparate results reported in the previous study by Wajapeyee et al. (2008) is that the tissue culture conditions required for the loss-of-function screen resulted in the selective outgrowth of antibiotic-resistant cell clones that had escaped oncogene-induced senescence. Active oncogenes promote DNA hyper-replication and damage (Bartkova et al., 2006; Di Micco et al., 2006) , and immortal melanocytic clones harboring oncogenes have been shown to accumulate additional secondary genetic changes (Sviderskaya et al., 2003; Yu et al., 2009 ). Consequently, we have limited the contribution of additional genetic alterations in our study by (1) excluding long-term antibiotic selection steps and reducing the duration of our experiments, (2) analyzing pooled cell populations rather than cell clones, and (3) repeating our shortterm experiments in several different primary human cell cultures. In support of this approach, p53-deficient melanocytes behaved as expected and responded to oncogenic B-RAF by inducing p16
INK4a (Zhuang et al., 2008) , whereas the equivalent antibiotic-selected cell clones generated by Wajapeyee et al. (2008) showed no induction of p16 INK4a . As there is no evidence that p53 loss interrupts the regulation of p16
INK4a
by the MAPK pathway, we are led to speculate that the p16
INK4a gene had been altered in those clones, especially given that both wild-type and p53 null melanocytes should respond to oncogenic N-RAS by induction of p16
INK4a expression (Haferkamp et al., 2009a ).
In conclusion, despite the use of several independent experimental strategies, we were unable to find evidence to support a critical role of IGFBP7 in mediating B-RAF-induced senescence in melanocytes, in contrast to the recent report in this journal. There is little doubt, however, that secreted factors play a significant role in senescence. Key components of the Wnt1, transforming growth factor b, plasmin, and interleukin signaling cascades reinforce senescence and potentially sensitize neighboring cells to proliferative arrest (reviewed in Acosta et al., 2008; Kuilman and Peeper, 2009 ). Paradoxically, some of these secreted factors can also exert protumorigenic effects depending on the cell type and tumor stage. This has important implications when considering the therapeutic applicability of agonists that promote senescence, and it is critical that the contribution and in vivo interactions of these secreted effectors are defined. 
RNA Extraction and Microarray Gene Expression Analysis
Total RNA was extracted from 10-20 mg of tumor. Tissue samples were homogenized using a high-speed agitation Polytron blender (Kinematica, Luzern, Switzerland) in the presence of Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA). Following homogenization, chloroform was added and the sample centrifuged. The upper phase was removed and mixed with 70% ethanol. The RNA was then isolated and purified with an RNeasy purification kit with DNase I digestion on the column (QIAGEN, Valencia, CA, USA). The quality of the RNA preparations was assessed using a Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA). The extracted total RNA was of high quality (RNA integrity number: 8-10). cRNA amplification and labeling with biotin were performed using the Illumina TotalPrep RNA amplification kit (Ambion, Austin, TX, USA) according to the manufacturer's directions starting with 250 ng total RNA. Gene expression analysis was performed using the Sentrix HumanRef-6 v.3.0 Expression BeadChip (Illumina, San Diego, CA, USA) and BeadStation system from Illumina according to manufacturer's instructions.
DNA Extraction and Genotyping
DNA was extracted from a 10-20 mg tumor tissue sample using the QIAGEN QIAamp DNA mini kit (QIAGEN). Briefly tissue was pulverized using liquid : G464R, G464V/E,  G466R, F468C, G469S, G469E, G469A, G469V, G469R, D594V/G, F595L,  G596R, L597S, L597R, L597Q, L597V, T599I, V600E, V600K, V600R, V600L , K601N, K601E. N-RAS SNPs: G12V/A/D, G12C/R/S, G13V/A/D, G13C/R/S, A18T, Q61L/R/P, Q61H, Q61E/K. DNA of nevi from three consecutive sections from the paraffin blocks was isolated using a DNA isolation kit (QIAGEN) according to the manufacturer's recommendations. Subsequently, the B-RAF V600E mutation was detected by real-time PCR as previously described (Benlloch et al., 2006) . Halaban et al., 1986) . HEK293T, fibroblasts, and all melanoma cell lines were grown in Dulbecco's modified Eagle's medium (GIBCO BRL) supplemented with 10% fetal bovine serum, HEPES, and glutamine. All cells were cultured in a 37 C incubator with 5% CO 2 . Cells were treated with media containing 40 mM PD98059 for 72 hr and the media with MEK inhibitor were replenished every 24 hr.
Lentiviral Transductions
Lentiviruses were produced in HEK293T cells as described previously (Haferkamp et al., 2009b) . Cells were infected using a multiplicity of infection (moi) between 5 and 10 to provide an efficiency of infection above 90%.
Constructs
The wild-type and mutant B-RAF cDNAs were kindly provided by Professor R. Marais (The Institute of Cancer Research, UK). An additional missense mutation in the wild-type B-RAF clone (C > G at nucleotide 634; NM_004333) was repaired using PCR overlap mutagenesis. The MYC-tagged wild-type and mutant B-RAF cDNAs were each cloned into the pCDH-CMV-MCS-EF1-copGFP lentiviral vector, which coexpresses copGFP (System Biosciences, Mountain View, CA, USA). The IGFBP7 shRNA sequences correspond to nucleotides 963-983 and 865-885 (NM_001553; Wajapeyee et al., 2008) . The V600E-specific B-RAF shRNA sequence corresponds to nucleotides 1853-1871 (NM_004333). The pRb-and p53-specific shRNAs have been described previously (Haferkamp et al., 2009a) . All shRNAs were cloned into the pSIH-H1-EF1-copGFP and pSIH-H1-Puro lentiviral vectors, which express copGFP or puromycin resistance, respectively (System Biosciences). The nonsilencing negative control shRNA did not show complete homology to any known human transcript and had the following sequence: 5 0 -TTAGAGGC-GAGCAAGACTA-3 0 .
Western Blotting
Total cellular proteins were extracted at 4 C using RIPA lysis buffer containing protease inhibitors (Roche, Basel, Switzerland). Proteins (30-50 mg) were resolved on 12% SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Secreted proteins were collected from the culture media, which were initially cleared by centrifugation. Four milliliters of the cleared media were centrifuged through 15 ml centricon centrifugal filter units (50 kDa cut off) (Millipore) at 4000 3 g for 30 min and the resulting supernatants were loaded onto 10 kDa centricon units and recentrifuged. The concentrated sample (100-200 ml) containing soluble IGFBP7 ($37 kDa) was collected and proteins (40 mg) were resolved on 12% SDS-polyacrylamide gels and transferred to Immobilon P-membranes (Millipore 
Indirect Immunofluorescence
Cells were seeded on coverslips in 12-well plates at 3 3 10 4 cells per well at each time point and incubated overnight. Cells were washed in phosphatebuffered saline (PBS) and fixed with 4% formaldehyde/PBS for 15 min at room temperature. Cells were rinsed three times with PBS, then permeabilized with 0.2% Triton X-100/PBS for 10 min, then rinsed and blocked in 10% FCS/PBS for 1 hr. Cells were incubated with primary antibodies for 50 min, washed then incubated with Alexa Fluor 594-conjugated secondary IgG (Molecular Probes, Carlsbad, CA, USA) and 1 mg/ml of the nuclear DNA stain 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 50 min. Primary antibodies used were Ki67 (MIB-1; DAKO, Glostrup, Denmark), trimethyl-histone H3 (Lys 9) (07-442; Millipore), and HMGA2 (HMG1-C, FL109; Santa Cruz). SA-b-Gal activity was detected as described previously (Dimri et al., 1995) .
Immunohistochemistry
Tissue arrays of nevi or melanomas were dewaxed before they were rehydrated by washing twice with absolute ethanol, two times with 70% ethanol, and finally by one rinse with bi-distilled water. Samples were antigen retrieved by heating at 90 C for 20 min in antigen retrieval solution (pH 6) (S1699; DAKO)
or by microwaving for 10 min in 10 mM sodium citrate (pH 6.0) and then cooled for 20 min. After blocking endogenous peroxidase the slides were incubated with goat anti-IGFBP7 antibody (C16; Santa Cruz) diluted 1:100 for 25 min to 2 hr, then washed with PBS. Subsequently, the slides were incubated with biotinylated anti-goat antibody (BA-5000; Vector Laboratories, Burlingame, USA or P0449; DAKO) for 25 min, slides were washed with PBS, incubated in streptavidin-HRP (K0690; DAKO) or streptavidin/biotin-HRP (Invitrogen) for 25 min, and placed in Vector NovaRed or 3,3 0 -diaminobenzidine substrate (DAB) for 10-15 min (Vector Laboratories). Sections were counterstained with hematoxylin and mounted. A pathologist performed the evaluation of the staining in a blinded manner.
Statistical Analysis
Scatter plots were used to illustrate the distribution of gene expression by B-RAF mutation status. Medians and interquartile ranges were applied to summarize the distributions, and the Mann-Whitney test was used to determine the differences between the B-RAF wild-type and B-RAF mutant populations. 
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